Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer

被引:32
作者
Noguchi, M [1 ]
Yahara, J [1 ]
Noda, S [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Urol, Kurume, Fukuoka 8300011, Japan
关键词
D O I
10.1016/S0090-4295(02)02583-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To investigate the usefulness of bone turnover markers as a modality for monitoring bone metastasis in patients with prostate cancer with bone metastasis. Methods. Serial measurements of pyridinoline cross-linked carboxyterminal telopepticle of type I collagen (ICTP), carboxyterminal pro-peptide of type I procollagen (PICP), prostate-specific antigen (PSA), and the percentage of the positive area on the bone scan were prospectively performed before and after hormonal therapy in 84 patients with prostate cancer with bone metastasis for median follow-up of 29 months. Results. Serial ICTP and PICP levels in 48 patients without progression of bone metastasis demonstrated a downward trend during treatment and were almost within the normal range by the end of follow-up. The remaining 36 patients, who had PSA failure with progression of bone metastasis, showed an upward trend for serial ICTP and PICP levels before the progression of bone metastasis. The rates of detecting bone progression using bone turnover markers were higher than those using PSA levels on the basis of the percentage of clinical effectiveness and receiver operating characteristic curves. Conclusions. Serial measurement of bone turnover markers is useful for monitoring the bone activity of prostate cancer and might detect early progression of bone metastasis in patients with PSA failure. (C) 2003, Elsevier Inc.
引用
收藏
页码:993 / 998
页数:6
相关论文
共 29 条
[1]  
Akimoto S, 1999, PROSTATE, V38, P28, DOI 10.1002/(SICI)1097-0045(19990101)38:1<28::AID-PROS3>3.0.CO
[2]  
2-M
[3]   Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].
Bubley, GJ ;
Carducci, M ;
Dahut, W ;
Dawson, N ;
Daliani, D ;
Eisenberger, M ;
Figg, WD ;
Freidlin, B ;
Halabi, S ;
Hudes, G ;
Hussain, M ;
Kaplan, R ;
Myers, C ;
Oh, W ;
Petrylak, DP ;
Reed, E ;
Roth, B ;
Sartor, O ;
Scher, H ;
Simons, J ;
Sinibaldi, V ;
Small, EJ ;
Smith, MR ;
Trump, DL ;
Vollmer, R ;
Wilding, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467
[4]  
CHARHON SA, 1983, CANCER, V51, P918, DOI 10.1002/1097-0142(19830301)51:5<918::AID-CNCR2820510526>3.0.CO
[5]  
2-J
[6]   COMPARISON OF SENSITIVITY AND ACCURACY OF TC-99(M)-PHOSPHATE BONE SCAN AND SKELETAL RADIOGRAPH IN DIAGNOSIS OF BONE METASTASES [J].
CITRIN, DL ;
BESSENT, RG ;
GREIG, WR .
CLINICAL RADIOLOGY, 1977, 28 (01) :107-117
[7]   DISODIUM PAMIDRONATE IDENTIFIES DIFFERENTIAL OSTEOCLASTIC BONE-RESORPTION IN METASTATIC PROSTATE-CANCER [J].
CLARKE, NW ;
MCCLURE, J ;
GEORGE, NJR .
BRITISH JOURNAL OF UROLOGY, 1992, 69 (01) :64-70
[8]   BONE ALKALINE-PHOSPHATASE AND PROSTATE-SPECIFIC ANTIGEN IN THE MONITORING OF PROSTATE-CANCER [J].
COOPER, EH ;
WHELAN, P ;
PURVES, D .
PROSTATE, 1994, 25 (05) :236-242
[9]   Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer [J].
Figg, WD ;
Ammerman, K ;
Patronas, N ;
Steinberg, SM ;
Walls, RG ;
Dawson, N ;
Reed, E ;
Sartor, O .
CANCER INVESTIGATION, 1996, 14 (06) :513-517
[10]  
FRANCINI G, 1993, CANCER EPIDEM BIOMAR, V2, P125